With An Additional Active Ingredient Patents (Class 514/6.5)
-
Publication number: 20110281794Abstract: A composition, an infusion solution, a method for treatment, and a kit for intravascular administration for treatment of a brain-dead, heart-beating, respirated, potential organ donor. The composition includes a non-adrenaline and amphetamine or an amphetamine-like substance. The composition may in addition include adrenaline, hydrocortisone, thyroxin, insulin, triiodotyronine, dopamine, a vasopressor agent, such as desmopressin, and methylprednisolone. The composition may be dissolved in pure water, Ringer's acetate solution or physiological sodium chloride solution. The composition is infused in such an amount as to maintain a mean arterial pressure of about 60 mmHg.Type: ApplicationFiled: December 30, 2009Publication date: November 17, 2011Applicant: VIVOLINE MEDICAL ABInventor: Stig Steen
-
Publication number: 20110280833Abstract: Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, and/or lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.Type: ApplicationFiled: June 24, 2011Publication date: November 17, 2011Applicant: CUREDM GROUP HOLDINGS, LLCInventors: Claresa S. Levetan, Loraine V. Upham
-
Publication number: 20110274758Abstract: AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to reverse an autoimmune diabetes condition in NOD mice in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.Type: ApplicationFiled: May 9, 2011Publication date: November 10, 2011Applicants: BAXTER INTERNATIONAL INC., University of Pittsburgh - Of the Commonwealth System of Higher Education, BAXTER HEALTHCARE S.A.Inventors: Larry R. Brown, Nick Giannoukakis, Kimberly A. Gillis, Massimo Trucco
-
Publication number: 20110275561Abstract: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients with insufficient glycemic control despite a therapy with an oral and/or a non-oral antidiabetic drug.Type: ApplicationFiled: October 15, 2009Publication date: November 10, 2011Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Eva Ulrike Graefe-Mody, Thomas Klein, Michael Mark, Hans-Juergen Woerle
-
Publication number: 20110269679Abstract: The present invention provides new antifibrillogenic agents and peptides, compositions and cells containing same, compositions that bind to same, effective therapeutics for preventing or delaying the progression of, e.g., Alzheimer's disease and diabetes, methods for optimizing antifibrillogenic agents, and methods of using the antifibrillogenic agents, peptides, compositions, and cells of the invention for detecting and/or inhibiting amyloid fibril formation.Type: ApplicationFiled: October 15, 2010Publication date: November 3, 2011Inventor: PAUL FRASER
-
Patent number: 8048854Abstract: The invention relates to insulin glargine which is modified by amidation, especially Gly(A21), Arg(B31), Arg amide (B32) human insulin (insulin glargine amide).Type: GrantFiled: January 7, 2009Date of Patent: November 1, 2011Assignee: Sanofi-Aventis Deutschland GmbHInventors: Paul Habermann, Frank Zocher
-
Publication number: 20110263494Abstract: Disclosed are compounds of Formula (I) wherein: one of A and D is —N— and the other of A and D is —C—; or enantiomers, diastereomers, or pharmaceutically-acceptable salts thereof. Also disclosed are methods of using such compounds to modulate the function of glucocorticoid receptor activity and pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: October 30, 2008Publication date: October 27, 2011Inventors: T.G. Murali Dhar, Hai-Yun Xiao
-
Publication number: 20110257085Abstract: Physical crystal structures of a compound of the formula I: are provided including the free base monohydrate thereof (form H-1) and the hydrochloric acid salt thereof, including hydrochloric acid salt containing 0.75 equivalent of H2O (form H0.75-3) and hydrochloric acid salt containing 2 equivalents of H2O (form H2-1), and hydrochloric acid salt Pattern P-5, preferably in substantially pure form, and other forms as described herein, pharmaceutical compositions containing structures of compound I or IA, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.Type: ApplicationFiled: April 6, 2011Publication date: October 20, 2011Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Jack Z. Gougoutas, Mary F. Malley, John D. DiMarco, Xiaotian S. Yin, Chenkou Wei, Jurong Yu, Truc Chi Vu, Gregory Scott Jones, Scott A. Savage
-
Publication number: 20110244023Abstract: A composition suitable for use in a transdermal delivery patch for administration of a biologically active compound, the composition comprising a phosphate compound of tocopherol and a polymer carrier.Type: ApplicationFiled: May 18, 2010Publication date: October 6, 2011Applicant: PHOSPHAGENICS LIMITEDInventors: Jeremy Cottrell, Giacinto Gaetano, Mahmoud El-Tamimy, Nicholas Kennedy, Paul David Gavin
-
Publication number: 20110237505Abstract: Disclosed are methods of modulating the expression of genes linked to adipocytokine signaling, carbohydrate metabolism, fatty acid metabolism, arachidonic acid metabolism, PPAR signaling, insulin signaling, lipid metabolism, extracellular matrix (ECM)-receptor interaction, or combinations thereof, methods of treating hyperlipidemia, obesity, excessive cholesterol, cardiovascular disease, liver disease, diabetes, or combinations thereof, and methods of stimulating glucose uptake in an animal in need thereof, comprising administering a composition comprising at least one isolated glyceollin to said animal.Type: ApplicationFiled: December 22, 2010Publication date: September 29, 2011Applicant: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventors: Matthew E. BUROW, Stephen M. BOUE, Thomas T.Y. WANG, Deepak BHATNAGAR, Charles E. WOOD, Mark A. HEIMAN
-
Publication number: 20110230403Abstract: The present invention relates to compounds of formula I and pharmaceutically acceptable salts, to formulations and uses of the compounds of formula (I) in the treatment of metabolic disorders.Type: ApplicationFiled: September 17, 2009Publication date: September 22, 2011Applicant: NOVARTIS AGInventors: P. Venkata Palle, Dumbala Srinivas Reddy, Suresh Eknath Kurhade, Debnath Bhuniya
-
Publication number: 20110217260Abstract: A method of enhancing eyelash and eye brow hair growth utilizes insulin and/or IFG-1 alone or in combination with other known hair growth promoting therapeutic, pharmaceutical, biochemical and biological agents to increase the effect of various therapeutic hair regrowth strategies to enhance eyelash and eye brow hair growth.Type: ApplicationFiled: March 4, 2010Publication date: September 8, 2011Inventors: Totada R. Shantha, Erica Maya Shantha, Jessica Gowramma Shantha, Usha T. Shantha Martin, Lauren Asha Shantha
-
Publication number: 20110218142Abstract: The present invention relates to inhibitors of post-proline cleaving enzymes, such as inhibitors of dipeptidyl peptidase IV, as well as pharmaceutical compositions thereof, and methods for using such inhibitors. In particular, the inhibitors of the present invention are improved over those in the prior art by selection of particular classes of sidechains in the P1 and/or P2 position of the inhibitor that contain a carboxylic acid moiety. The compounds of the present invention can have a better therapeutic index, owing in part to reduced toxicity and/or improved specificity for the targeted protease.Type: ApplicationFiled: May 16, 2011Publication date: September 8, 2011Applicant: Trustees of Tufts CollegeInventors: William W. Bachovchin, Hung-sen Lai, Wengen Wu
-
Publication number: 20110207661Abstract: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.Type: ApplicationFiled: November 1, 2010Publication date: August 25, 2011Applicant: Theracos, Inc.Inventors: Yuanwei Chen, Huawei Cheng, Shengbin Li, Yuelin Wu, Yan Feng, Binhua Lv, Baihua Xu, Brian Seed, Michael J. Hadd, Yanli Song, Jiyan Du, Congna Wang, Jacques Y. Roberge
-
Publication number: 20110192748Abstract: Pharmaceutical compositions comprising 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.Type: ApplicationFiled: April 21, 2011Publication date: August 11, 2011Applicant: Takeda Pharmaceutical Company LimitedInventors: Ronald J. Christopher, Paul Covington
-
Publication number: 20110183901Abstract: Methods related to the treatment of diabetes and improving the control of blood glucose levels are provided. In particular, methods are provided for effectively reducing postprandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration. Additionally, methods for effectively reducing post-prandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration along with a long-acting basal insulin.Type: ApplicationFiled: March 31, 2011Publication date: July 28, 2011Applicant: MANNKIND CORPORATIONInventors: Wayman Wendell Cheatham, Anders Hasager Boss
-
Publication number: 20110182853Abstract: The present invention is related to the discovery of a novel class of neural progenitor cells, which proliferate in response to platelet derived growth factor (PDGF) and differentiate into neurons and oligodendrocytes but not astrocytes. Progeny of the progenitor cells can be obtained by culturing brain tissue in PDGF without serum, epidermal growth factor (EGF), fibroblast growth factor 2, or transforming growth factor alpha. Upon subculturing into EGF-containing media, these progeny cells can proliferate and form neurospheres, whereas PDGF has no such effect.Type: ApplicationFiled: April 7, 2011Publication date: July 28, 2011Applicant: STEM CELL THERAPEUTICS INC.Inventors: Samuel Weiss, Andrew K. Chojnacki
-
Publication number: 20110171159Abstract: This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.Type: ApplicationFiled: October 18, 2010Publication date: July 14, 2011Applicant: NOVARTIS AGInventors: Gregory Raymond BEBERNITZ, Mark G. BOCK, Dumbala Srinivas REDDY, Atul Kashinath HAJARE, Vinod VYAVAHARE, Sandeep Bhausaheb BHOSALE, Suresh Eknath KURHADE, Videsh SALUNKHE, Nadim S. SHAIKH, Debnath BHUNIYA, P. Venkata PALLE, Lili FENG, Jessica LIANG
-
Publication number: 20110166065Abstract: Compositions and methods are provided for decreasing blood glucose levels in an animal, comprising administering to said animal an antisense inhibitor of glucose-6-phosphatase translocase expression alone or in combination with at least one glucose-lowering drug. Also provided are compositions and methods for treating diabetes and other metabolic disorders.Type: ApplicationFiled: March 10, 2011Publication date: July 7, 2011Applicant: Isis Pharmaceuticals, Inc.Inventors: Sanjay Bhanot, Kenneth W. Dobie
-
Publication number: 20110158932Abstract: Methods and compositions containing a berberine compound or berberine related or derivative compound are provided for the prevention and treatment of hyperlipidemia, elevated cholesterol, and/or cardiovascular disease in mammalian subjects. The methods and compositions of the invention are effective for prevention and treatment of atherosclerosis, coronary artery disease, angina pectoris, carotid artery disease, stroke, cerebral arteriosclerosis, high blood pressure, myocardial infarction, cerebral infarction, restenosis following balloon angioplasty, intermittent claudication, dyslipidemia post-prandial lipidemia or xanthoma.Type: ApplicationFiled: December 8, 2008Publication date: June 30, 2011Inventors: Jian-Dong Jiang, Jing Wei, Wei-Jia Kong, Li-Xun Zhao, Dan-Qing Song
-
Publication number: 20110158935Abstract: Disclosed are drug delivery systems for the delivery of small molecule and macromolecular drugs. More particularly, disclosed are substituted analogs of 3,6-di(alkyl-4 aminobutyl)-2,5-diketopiperazine (which may also be referred to DKP), their use in the formulation of both small molecule and macromolecular drugs including therapeutic, prophylactic and diagnostic agents, stabilizing agents and systems for their delivery.Type: ApplicationFiled: December 29, 2009Publication date: June 30, 2011Inventor: Kelly Sullivan Kraft
-
Publication number: 20110152185Abstract: Pharmaceutical composition for parenteral administration comprising a basal insulin peptide and an insulinotropic GLP-1 peptide comprising at least 6 zinc atoms per 6 insulin molecules.Type: ApplicationFiled: November 14, 2008Publication date: June 23, 2011Applicant: Novo Nordisk A/SInventors: Anne Plum, Dorte Bjerre Steensgaard, Jens Kaalby Thomsen, Morten Schlein, Anne Sofie Kajaer Markussen, Christian Poulsen
-
Publication number: 20110150830Abstract: The invention relates to covalent conjugates between endoperoxides and small peptides and organic compounds that bind to molecular cavities on the transferrin or lactoferrin receptor, and the use of compositions comprising these conjugates to treat cancer, hyperproliferative disorders, inflammatory diseases, and infections.Type: ApplicationFiled: February 14, 2011Publication date: June 23, 2011Applicant: WASHINGTON, UNIVERSITY OFInventors: Tomikazu Sasaki, Henry Chiu-Yuen Lai, Narendra Pal Singh, Steve J. Oh
-
Publication number: 20110144011Abstract: Diabetic and other patients are treated using an aggressive form of Pulsed Insulin Therapy in which a pre-treatment blood sugar level in the patient of at least 250-300 mg/dL, and the patient is treated with at least first and second cycles, each cycle comprising (1) pulsing a recombinant human insulin to the patient in concentrations of more than 10% to achieve a target intra-treatment blood sugar level (BSL) swing of more than 100 mg/dL, and (2) raising the blood sugar level to at least 250-300 mg/dL.Type: ApplicationFiled: December 14, 2010Publication date: June 16, 2011Inventors: Michael McCarthy, Marc Rose
-
Publication number: 20110142800Abstract: This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, methods for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.Type: ApplicationFiled: August 11, 2009Publication date: June 16, 2011Applicant: Oramed Ltd.Inventors: Miriam Kidron, Ehud Arbit
-
Publication number: 20110118179Abstract: An insulin compound coupled to a modifying moiety having a formula: —X—R1—Y-PAG-Z—R2 ??(Formula VI) where, X, Y and Z are independently selected linking groups and each is optionally present, and X, when present, is coupled to the insulin compound by a covalent bond, either R1 or R2 is is a lower alkyl, optionally including a carbonyl group, and when R1 is a lower alkyl, R2 is a capping group, and PAG is a linear or branched carbon chain incorporating one or more alkalene glycol moieties, and optionally incorporating one or more additional moieties selected from the group consisting of —S—, —O—, —N—, and —C(O)—.Type: ApplicationFiled: January 24, 2011Publication date: May 19, 2011Inventors: Balasingam Radhakrishnan, Diti Aggarwal, Michelle Ferro, Kenneth D. James, Navdeep B. Malkar, Mark A. Miller, Monica Puskas, Nnochiri N. Ekwuribe
-
Publication number: 20110118178Abstract: A method for the treatment of diabetes mellitus type 2 comprising administering (d) desPro36Exendin-4(1-39)-Lys6-NH2 or/and a pharmaceutically acceptable salt thereof, (e) insulin glargine or/and a pharmaceutically acceptable salt thereof, and (f) metformin or/and a pharmaceutically acceptable salt thereof, to a subject in need thereof.Type: ApplicationFiled: November 13, 2009Publication date: May 19, 2011Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Louise SILVESTRE, Elisabeth SOUHAMI, Xiaodan WEI
-
Publication number: 20110104206Abstract: The present disclosure relates to methods and compositions for the topical sustained delivery of therapeutic agents. Topical application of compositions containing a muscle fasciculating agent result in the sustained release of any therapeutic agent contained within the composition. More particularly, topical application of such compositions to the outer surface of the eyelid of a patient results in increased absorption and sustained release of the therapeutic agent into the eyes or systemically.Type: ApplicationFiled: October 29, 2010Publication date: May 5, 2011Inventors: Padma NANDURI, T. Aaron DYER
-
Publication number: 20110105393Abstract: Methods are disclosed herein for increasing the number of stem cells or precursor cells. The number of stem cells can be increased by increasing survival and/or cell proliferation of the cells. The methods include contacting the cells with an effective amount of a Notch ligand, an effective amount of a growth factor, and an effective amount of angiopoietin-2 (Ang-2). In several embodiments, the methods include contacting the cells with an effective amount of a Jak inhibitor. In several non-limiting examples, the growth factor is insulin or glial derived neurotrophic factor (GDNF), or a combination thereof. In additional non-limiting examples, the Notch ligand is Delta. The cells can be in vivo or in vitro. Methods are also disclosed here for the treatment of a neurodegenerative disorder or spinal cord injury in a subject. In several non-limiting examples, the subject has Parkinson's disease or Alzheimer's disease.Type: ApplicationFiled: August 14, 2008Publication date: May 5, 2011Inventors: Andreas Androutsellis-Theotokis, Ronald D.G. McKay
-
Publication number: 20110097367Abstract: A method of making and using a monolithic alginate implant is described. The implant is formed by providing an uncrosslinked, highly pure and high molecular weight alginate solution and injecting the alginate solution into a patient at a predetermined site to form a gel body comprising the monolithic alginate implant. Spontaneous crosslinking of the monolithic alginate implant occurs at the predetermined site without the addition of an exogenous crosslinker. The implant may be used for treating medical conditions requiring support of sphincter musculature, reconstructive surgery, or cosmetic reconstruction, for the treatment of wrinkles on the hand, face, or décolleté, or for increasing volume, for example in the case of (HIV-induced) lipoatrophy of the breasts, and for the treatment of selected diseases, including gastrooesophageal reflux disease, urinary incontinence or vesicoureteral reflux disease.Type: ApplicationFiled: January 9, 2009Publication date: April 28, 2011Inventors: Christine Wallrapp, Herma Glöckner, Roland Reiner, Frank Thürmer
-
Publication number: 20110098220Abstract: The present invention provides improved methods and kits for treating the long-term complication of diabetes that reduce the risk of the patient developing hypoglycemia during C-peptide therapy. The use of such methods and kits, can also maintain good glycemic control, and avoid excessive weight gain that may otherwise be associated with excessive insulin administration or caloric intake during C-peptide therapy.Type: ApplicationFiled: March 4, 2010Publication date: April 28, 2011Applicant: CEBIX ABInventors: John Wahren, Karin Ekberg, James Callaway
-
Publication number: 20110077197Abstract: The invention relates to novel insulin analogs having a basal time-action profile, which are characterized by the following features: a) the B chain end consists of an amidated basic amino acid residue such as lysine or arginine amide; b) the N-terminal amino acid residue of the insulin A chain is a lysine or arginine radical; c) the amino acid position A8 is occupied by a histidine radical; d) the amino acid position A21 is occupied by a glycine radical; and e) one or more substitutions and/or additions of negatively charged amino acid residues are carried out in the positions A5, A15, A18, B-1, B0, B1, B2, B3 and B4.Type: ApplicationFiled: June 22, 2010Publication date: March 31, 2011Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Paul HABERMANN, Gerhard SEIPKE, Roland KURRLE, Gunter MULLER, Mark SOMMERFELD, Norbert TENNAGELS, Georg TSCHANK, Ulrich WERNER
-
Publication number: 20110065634Abstract: The present invention relates to compounds of general formula (I), wherein ring A, ring B, R1, R2, R3, Z, and L1 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.Type: ApplicationFiled: May 13, 2009Publication date: March 17, 2011Inventors: William J. Greenlee, Andrew Stamford, Michael W. Miller, Duane Eugene DeMong
-
Publication number: 20110052678Abstract: A method for treating age related macular degeneration uses insulin preparation applied topically in a therapeutically effective amount to an affected conjunctival sac of the eye. The topically effective dose is delivered to the fovea centralis and macula lutea. In other embodiments, additional therapeutic, pharmaceutical, biochemical, nutriceutical, biological (monoclonal antibodies and others) agent or compound, and organic and inorganic agents are also applied to the afflicted site through the conjunctival sac and choroidal vascular system of the eye. IGF-1 may be applied as well with or without insulin to treat ARMD.Type: ApplicationFiled: November 5, 2010Publication date: March 3, 2011Inventors: Totada R. Shantha, Jessica Shantha, Erica Maya Shantha
-
Publication number: 20110038827Abstract: The present invention relates to the use of isosteviol, steviol, and related compounds for elevating the plasma HDL-cholesterol level. The invention furthermore relates to the use of these compounds for reducing the body weight of a subject and/or lowering the plasma triglyceride level of a subject, including a concomitant elevation of the plasma HDL-cholesterol level. Preferably the compounds used are isosteviol and/or steviol, or pharmaceutically acceptable salts, solvates or prodrugs thereof. The compounds may furthermore be administered in combination with one or more further active compounds, such as e.g. LDL-cholesterol lowering agents. The invention furthermore relates to a method for elevating the plasma HDL-cholesterol level in a subject by administering to a subject in need of such treatment a plasma HDL-cholesterol level elevating amount of the compounds, described herein.Type: ApplicationFiled: December 5, 2008Publication date: February 17, 2011Inventors: Kjeld Hermansen, Per Bendix Jeppesen
-
Publication number: 20110034378Abstract: The present invention relates to a combination, such as a combined preparation or pharmaceutical composition comprising: (a) compound of formula (I), and/or (II) or a pharmaceutically acceptable salt thereof; (b) at least one therapeutic agent selected from the group consisting of: an antihypertensive agent; an antidiabetics agent; a hypolipidemic agent; an antiplatelet agent; an antiobesity agent; an antithrombotic agent; an agent for diabetic vascular complications; and an agent for treatment of heart failure; or a pharmaceutically acceptable salts thereof, optionally in presence of a pharmaceutically acceptable carrier for separate, simultaneous or sequential use. The present invention also relates to a use of such combination for the treatment of mammal including human being. R1, R2, R3, R1, R2, R3, R4, R5, X, Y, A and B and m are as defined in the specification.Type: ApplicationFiled: January 21, 2009Publication date: February 10, 2011Inventors: Chaitanya Dutt, Deepa Joshi, Ram Gupta, Kumarprafull Chandra
-
Publication number: 20110034375Abstract: The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I. where R1, R1a, R1b, A, R3, R4, R5, R5b and R6 are as defined herein.Type: ApplicationFiled: October 19, 2010Publication date: February 10, 2011Inventors: William N. Washburn, Saleem Ahmad, Andres S. Hernandez
-
Publication number: 20110020279Abstract: This invention is for a method of treatment of rabies once the patient develops signs and symptoms of rabies with the intent to save the patients from death and disability using insulin combined with various anti rabies viral therapeutic, pharmaceutical, biochemical, and biological agents or compounds with added supportive therapies administered through OM, SAS, IVB, IV, and IA routes. An embodiment provides devices for intranasal delivery of therapeutic agents to olfactory mucosal area. Another embodiment uses the technology to deliver the therapeutic, pharmaceutical, biochemical, and biological agents or compounds to the subarachnoid space and ventricular system by using continuous catheters and Ommaya reservoir at the same time. The present method incorporates breaking the blood brain barrier to allow the entry of the anti rabies therapeutic agents into the neuropile. Additionally, an embodiment incorporates cooling of the brain and inducing hibernation to preserve the brain from damage due to rabies.Type: ApplicationFiled: September 29, 2010Publication date: January 27, 2011Inventor: Totada R. Shantha
-
Publication number: 20110020435Abstract: The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of insulin or an analog thereof.Type: ApplicationFiled: October 1, 2010Publication date: January 27, 2011Applicant: Aegis Therapeutics LLCInventor: Edward T. Maggio
-
Publication number: 20110020471Abstract: Erythrocyte ATP-release modulators and composition and methods for their use to potentiate serum glucose clearance and vasodilation; methods for prophylactic or palliative therapy of glucose processing or vascular disorders; processes for preparing the modulators and compositions comprising them; and kits therefor.Type: ApplicationFiled: September 23, 2009Publication date: January 27, 2011Applicants: Wayne State University, Board of Directors of Michigan State UniversityInventors: Dana Spence, Gavin Edmund Reid
-
Publication number: 20110021974Abstract: The invention relates to a method of instilling insulin ophthalmic drops in the conjunctival sac for treating retinitis pigmentosa due to any etiological factors both genetic and non genetic. The retinitis pigmentosa is treated with Insulin and/or IGF-I with or without known anti-retinitis pigmentosa therapeutic, pharmaceutical, biochemical, and biological agents or compounds. The invention furthermore uses this method as prophylactic on patients where the patients are predisposed to develop retinitis pigmentosa. The invention additionally treats other oculopathies associated with and/or contributing to retinitis pigmentosa.Type: ApplicationFiled: October 5, 2010Publication date: January 27, 2011Inventors: Totada R. Shantha, Jessica Shantha, Erica Maya Shantha
-
Publication number: 20110014247Abstract: This invention provides compositions that include a protein and at least two protease inhibitors, method for treating diabetes mellitus, and methods for administering same, and methods for oral administration of a protein with an enzymatic activity, including orally administering same.Type: ApplicationFiled: February 26, 2009Publication date: January 20, 2011Applicant: ORAMED LTD.Inventor: Miriam Kidron
-
Publication number: 20110002952Abstract: Novel non-steroidal compounds are provided which are useful in treating diseases or disorders associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity, including metabolic and inflammatory and immune diseases or disorders, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a prodrug ester thereof, or a pharmaceutically-acceptable salt thereof, in which: Z is heterocyclo or heteroaryl; -A is a 5- to 8-membered carbocyclic ring or a 5- to 8-membered heterocyclic ring; B1 and B2 rings are pyridyl rings, wherein the B1 and B2 rings are each fused to the A ring and the B1 ring is optionally substituted by one to three groups which are the same or different and are independently selected from R1, R2, and R4, and the B2 ring is optionally substituted by one to three groups which are the same or different and are independently selected from R3, R7, and R3 71, J2, and J3 are at each occurrence the same or different and are independently -AIQA2-; Q isType: ApplicationFiled: February 5, 2009Publication date: January 6, 2011Inventors: Jingwu Duan, David S. Weinstein, Bin Jiang
-
Publication number: 20110003740Abstract: The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitisers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present invention further relates to compounds and agents and compositions thereof for use in the treatment methods.Type: ApplicationFiled: January 25, 2008Publication date: January 6, 2011Applicant: VERVA PHARMACEUTICALS LTD.Inventors: Gregory Royce Collier, Kenneth Russell Walder, James Alexander Campbell, Juan-Carlos Molero-Navajas, Nicky Konstantopoulos, Guy Yeoman Krippner
-
Publication number: 20100330021Abstract: Compounds of the formula R—NH-Q??(I) provide pharmacological agents which are glucokinase activators and thus may be employed for the treatment of glucokinase mediated conditions. Accordingly, the compounds of formula (I) may be employed for prevention and treatment of impaired glucose tolerance, Type 2 diabetes and obesity.Type: ApplicationFiled: September 3, 2010Publication date: December 30, 2010Inventor: Gregory Raymond Bebernitz
-
Publication number: 20100317575Abstract: The invention relates to a pharmaceutical composition comprising a pyrazole-O-glucoside derivative selected from the group of compounds (1) to (29) according to claim 1 in combination with at least one second therapeutic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.Type: ApplicationFiled: January 18, 2008Publication date: December 16, 2010Applicants: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, AJINOMOTO CO., INC.Inventors: Sabine Pinnetti, Ruediger Streicher, Leo Thomas, Klaus Dugi
-
Publication number: 20100311651Abstract: Use of medicament for life saving treatment of critically ill patients and method of treatment. The medicament comprises a GLP-1 compound which effectively controls the blood glucose level.Type: ApplicationFiled: July 2, 2009Publication date: December 9, 2010Applicant: Novo Nordisk A/SInventors: Lotte Bjerre Knudsen, Johan Selmer, Kristian Tage Hansen
-
Publication number: 20100310542Abstract: The present disclosure relates to compositions and methods for accelerating the healing process of wounds, increasing the closure of skin wounds, and decreasing inflammation at the site of a skin wound. Specifically, the disclosure relates to compositions comprising a delta-PKC activator, an alpha-PKC inhibitor, and a pharmaceutically acceptable carrier that is free of Ca2+ and Mg2+ cations.Type: ApplicationFiled: July 30, 2008Publication date: December 9, 2010Applicant: HEALOR LTD.Inventors: Tamar Tennenbaum, Liora Braiman-Wiksman, Inessa Solomonik, Ofra Levy-Hacham, Ephraim Brener
-
Publication number: 20100310637Abstract: This invention relates to compositions and methods for lowering intraocular pressure and treatment and/or prevention of glaucoma and ocular hypertension. The invention provides insulin, isoforms of insulin, analoges of insulin, fragments of insulin peptide and other products of protein/gene engineered modifications of insulin for the lowering of intraocular pressure. The invention also provides insulin, isoforms of insulin, analoges of insulin, fragments of insulin and other products of protein/gene engineered modifications of insulin for increasing the success of glaucoma surgical procedures. The invention further provides insulin, isoforms of insulin, analoges of insulin, fragments of insulin and other products of protein/gene engineered modifications of insulin for neuroprotection of retinal ganglion cells.Type: ApplicationFiled: October 12, 2008Publication date: December 9, 2010Inventor: Muhammad Abdulrazik
-
Publication number: 20100292141Abstract: An inhalable nasal powder preparation of insulin and its preparing process are provided. The powder inhalation is consisting of self-emulsifying freeze-dried powder and pharmaceutically acceptable carriers. The dry powder comprises insulin, fat(s), emulsifier(s), antioxidant(s), supporting agent(s), bio-gel adhesive(s), and pH modifier(s), wherein the emulsifier is a mixture of lecithin and Tween 80, and the amount of fat in the formulation is determined by the surface area and the particle diameter of oil droplet.Type: ApplicationFiled: December 29, 2008Publication date: November 18, 2010Applicant: SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRYInventors: Fang Jin, Bokai Lei, Cong Wen